Stereotaxis, Inc. (STXS) Form 10-Q — Aug 12, 2026
Stereotaxis reported Q2 2026 revenue of $7.7 million, down 13% from $8.8 million a year earlier, with a net loss of $4.5 million that widened from $3.8 million. Quarterly EPS was $(0.05), flat with the prior-year quarter. The mix shifted sharply: systems revenue roughly halved to $1.5 million on lower sales volume, while disposables, service and accessories grew 7% to $6.2 million, helped by the MAGiC ablation catheter. Overall gross margin improved to 58% from 52% on product mix.
Key figures
- Revenue
- 7670000
- Revenue Yoy
- -13%
- Total Assets
- 55582000
- Cash Position
- 10491000
- Shares Outstanding
- 100202178
- Total debt
- 0
- H1 2025 revenue
- 16270000
- H1 2026 revenue
- 13961000
- Q2 2025 revenue
- 8798000
- Q2 gross margin
- 58% vs 52% prior year
- Working capital
- 11200000
- Robocath max earnout
- 25000000
- Atm remaining capacity
- 49300000
- Atm avg price per share
- 2.34
- Atm shares sold h1 2026
- 2361579
- Q2 2025 systems revenue
- 3038000
- Q2 2026 systems revenue
- 1479000
- Atm net proceeds h1 2026
- 5300000
- Atm gross proceeds h1 2026
- 5500000
- Robocath upfront consideration
- 20000000
- Cumulative net losses since inception
- 593700000
- Apt earnout h1 2026 revaluation charge
- 1400000
- Q2 disposables service accessories revenue
- 6191000
- Remaining performance obligations system contracts
- 9300000
Price after filing
Close on the filing date to close N calendar days later (from $1.40). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.